The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Analysts are particularly optimistic about the demand for tirzepatide, the active ingredient in Eli Lilly's flagship products Mounjaro and Zepbound. Eli Lilly's product portfolio is anchored by ...

Analysts are particularly optimistic about the demand for tirzepatide, the active ingredient in Eli Lilly's flagship products Mounjaro and Zepbound. Eli Lilly's product portfolio is anchored by its ...

US-based pharmaceutical company Eli Lilly is planning to launch Mounjaro, an anti-diabetes and weight loss drug in India by 2025 after regulatory approvals, reported News18 citing officials from ...

The results come after the maker of weight-loss drugs Zepbound and Mounjaro in January lowered expectations for its fourth-quarter sales. Eli Lilly (LLY) is set to report fourth-quarter earnings ...

Truist raised the firm’s price target on Eli Lilly (LLY) to $1,038 from $1,029 ... Omvoh and Kisunla and Mounjaro market expansion, the analyst tells investors in a research note.

Eli Lilly and Company LLY will report its fourth ... top-line growth is expected to have been driven by demand growth for Lilly’s FDA-approved tirzepatide medicines, diabetes drug Mounjaro and weight ...